滚动资讯
FierceBiotechAvalyn aims for $182M IPO to fund phase 3 trials of reformulated respiratory drugsThermo FisherThermo Fisher Scientific Q1 Earnings Call Highlights - Yahoo FinanceAgilentDoes Agilent (A) Settling Axion Dispute Clarify Its Push Into Cloud Lab Data Recurring Revenues? - simplywall.st10x Genomics BlogWhy 10x Genomics (TXG) Shares Are Trading Lower Today - Yahoo Finance10x Genomics BlogLiquidCell Dx 任命前 Foundation Medicine、10x Genomics 和 IDT 高管 Mirna Jarosz 为首席执行官；任命前 Foundation Medicine 首席医疗官 Vincent A. Miller 博士为高级战略顾问 - BioSpaceThermo FisherThermo Fisher Scientific: Why A Slow Q1 Does Not Reflect The Growth Opportunities - Seeking AlphaMOONS'阿尔忒弥斯计划将如何助美国打造月球基地AgilentAgilent Technologies Inc (A) Shares Fall 5.0% -- What GF Score o - GuruFocusThermo FisherThermo Fisher Scientific Inc. stock falls Thursday, underperforms market - MarketWatchFierceBiotech尽管存在数据隐忧，罗氏口服SERD仍有望成为公司史上最大产品：高管FierceBiotechRegeneron ushers in new genetic medicine era with groundbreaking gene therapy approvalThermo FisherThermo Fisher CEO says onshoring push will bring a ‘tailwind’ for the Waltham company - The Business Journals
FierceBiotech 2026年4月24日

Avalyn aims for $182M IPO to fund phase 3 trials of reformulated respiratory drugs

Avalyn aims for $182M IPO to fund phase 3 trials of reformulated respiratory drugs

原文
暂时没有全文，请查看原始来源。